Pros and cons of current brain tumor imaging

BM Ellingson, PY Wen, Martin van den Bent, TF Cloughesy

Research output: Contribution to journalArticleAcademicpeer-review

41 Citations (Scopus)

Abstract

Over the past 20 years, very few agents have been approved for the treatment of brain tumors. Recent studies have highlighted some of the challenges in assessing activity in novel agents for the treatment of brain tumors. This paper reviews some of the key challenges related to assessment of tumor response to therapy in adult high-grade gliomas and discusses the strengths and limitations of imaging-based endpoints. Although overall survival is considered the "gold standard" endpoint in the field of oncology, progression-free survival and response rate are endpoints that hold great value in neuro-oncology. Particular focus is given to advancements made since the January 2006 Brain Tumor Endpoints Workshop, including the development of Response Assessment in Neuro-Oncology criteria, the value of T2/fluid-attenuated inversion recovery, use of objective response rates and progression-free survival in clinical trials, and the evaluation of pseudoprogression, pseudoresponse, and inflammatory response in radiographic images.
Original languageUndefined/Unknown
Pages (from-to)2-11
Number of pages10
JournalNeuro-Oncology
Volume16
DOIs
Publication statusPublished - 2014

Cite this